在线国产一区二区_成人黄色片在线观看_国产成人免费_日韩精品免费在线视频_亚洲精品美女久久_欧美一级免费在线观看

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Headlines mislead on CoronaVac efficacy

By Zhang Zhihao | chinadaily.com.cn | Updated: 2021-01-13 15:42
Share
Share - WeChat
A display shows packages of vaccine candidate for SARS-CoV-2 by Sinovac Biotech in Beijing on Sept 24, 2020. [Photo/Agencies]

The 50.4 percent efficacy rate for the COVID-19 vaccine candidate made by China's Sinovac Biotech is only accurate under the most stringent testing settings, with the broadest of number of symptoms taken into account — many of which were not included in similar studies done by other vaccine developers, Chinese and Brazilian experts said.

Many media outlets are taking this figure out of context to criticize the Chinese vaccine, but this number alone is not an accurate representation of the vaccine's potency in a normal population, nor is it a justification not to use the vaccine, which has been proved to be safe, easy to store and transport, and is effective in preventing severe cases, they added.

On Tuesday, officials and researchers from Sao Paulo-based Butantan Institute, which is responsible for running the phase three clinical trial for CoronaVac, an inactivated vaccine candidate produced by Sinovac, announced they had submitted new data on the trial's progress in Brazil to the national health regulator for emergency use approval.

The data showed the shot was 100 percent effective in preventing severe cases, and had a 78 percent efficacy rate for volunteers with mild to severe cases of COVID-19 with excellent safety profile. It also has advantages in terms of logistics as it can be stored in a standard refrigerator at 2 to 8 degrees Celsius.

However, when all volunteers are considered, including those with "very mild" cases of COVID-19 that required no medical assistance, the total efficacy rate drops to 50.4 percent.

Ricardo Palácios, medical director of clinical research at Butantan Institute, said in a news briefing on Tuesday the inclusion of these very light cases represented the most stringent test for the vaccine, characterized by covering the broadest number of symptoms and intense exposure to COVID-19.

"We deliberately chose the most challenging conditions, and would like to capture even the subtlest of symptoms. These criteria have not been included on similar studies elsewhere," he said, adding if a vaccine can succeed even in the most demanding setting, "it would prove the vaccine would work well in normal conditions."

Rosana Richtman, a consultant on national immunization program for the Ministry of Health of Brazil, said in the press briefing the "most important number is 78 percent [efficacy rate]", which was first released by the Butantan Institute last week.

"A 78 percent effective vaccine can reduce the workload of our medical workers and alleviate the fear caused by the novel coronavirus to our people," she said. "The best vaccine is the one that is available to our people."

Natalia Pasternak, the president of Brazil's Science Question Institute, a non-profit organization on promoting scientific literacy, said CoronaVac may not be the perfect vaccine against COVID-19, but it is a vaccine that is compatible with Brazil's local production, cold chain logistics and distribution networks.

"We have a vaccine that is perfectly capable of preventing disease and death," she said. Even if the vaccine can only reduce the risk of the disease by around 50 percent in general, the benefits of preventing severe cases are still great, she said.

Wang Guiqiang, head of Peking University First Hospital's department of infectious diseases, said the clinical standards in the Brazilian trial are relatively higher than similar trials conducted elsewhere in the world, so "it is no surprise its efficacy rate is lower under certain circumstances."

"During a global pandemic, the purpose of vaccine is to reduce the number of patients and the workload of hospitals, so the medical system doesn't collapse under pressure," he said. "If the vaccine can prevent a majority of the public from seeking medical help and provide full protection against severe cases, it is still a significant result and well worth the effort."

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 欧美国产日韩在线观看 | 日韩精品一区二区三区在线播放 | 四影虎影ww4hu55.com | 中文字幕亚洲视频 | 成人一区二区三区在线观看 | 国产成人精品久久 | 夜夜操天天操 | 国产精品高清在线 | 久久国产精品成人免费观看的软件 | 国产成人一区 | 国产伦精品一区二区三区照片91 | 91亚洲精 | 欧美一区二区国产 | 五月婷婷在线视频 | 久久精品色欧美aⅴ一区二区 | 日韩免费视频一区二区 | 福利久久| 欧美喷潮久久久xxxxx | 99久久婷婷国产综合精品 | 日韩精品 | 国产成人精品无人区一区 | 欧美成人一区二区三区片免费 | 精品九九 | 91影库| 日韩欧美中文在线 | 国产一级免费 | 国产一区二区三区在线 | 国产综合精品一区二区三区 | 求av网站| 日本天天操| 成人免费视频www在线观看我 | 久久精品视频久久 | 久久99国产一区二区三区 | 久草视频在线首页 | 中文字幕一区二区三区四区 | 亚洲一区二区三区久久 | 亚洲视频在线免费观看 | 成人黄色免费在线视频 | 亚洲精品乱码8久久久久久日本 | 日本成人久久 | 日日摸天天做天天添天天欢 |